Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease.
J Alzheimers Dis
; 6(5): 483-8, 2004 Oct.
Article
em En
| MEDLINE
| ID: mdl-15505369
ABSTRACT
A new oral vaccine for Alzheimer's disease was developed using recombinant adeno-associated virus vector carrying Abeta cDNA (AAV/Abeta). Oral administration of the vaccine without adjuvant induced the expression and secretion of Abeta1-43 or Abeta1-21 in the epithelial cell layer of the intestine in amyloid precursor protein transgenic mice. Serum antibody levels were elevated for more than six months, while T cell proliferative responses to Abeta was not detected. Brain Abeta burden was significantly decreased compared to the control without inflammatory changes. This oral AAV/Abeta vaccine seems to be promising for prevention and treatment of Alzheimer's disease.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dependovirus
/
Vacinas contra Alzheimer
/
Doença de Alzheimer
/
Vetores Genéticos
Tipo de estudo:
Risk_factors_studies
Limite:
Animals
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article